ReviewFrontiers in oncology2026

Resistance mechanisms and countermeasures in CLDN18.2-positive tumors: from molecular networks to clinical practice.

Yutao Xia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.